Skip to main content
Article thumbnail
Location of Repository

Indirect Recruitment of a CD40 Signaling Pathway in Dendritic Cells by B7-DC Cross-Linking Antibody Modulates T Cell Functions

By Suresh Radhakrishnan, Rosalyn Cabrera, Kristina M. Bruns, Virginia P. Van Keulen, Michael J. Hansen, Sara J. Felts and Larry R. Pease


The human IgM B7-DC XAb protects mice from tumors in both therapeutic and prophylactic settings. Its mechanism of action is mediated by its binding to B7-DC/PD-L2 molecules on the surface of dendritic cells (DCs) to induce a multimolecular cap and subsequent activation of signaling cascades that determine a unique combination of DC phenotypes. One such phenotype, the B7-DC XAb-induced antigen accumulation in mTLR-matured DCs, has been linked to signaling through TREM-2, but the signals required for other DC phenotypes critical for the therapeutic effects in animal models remain unclear. Here, FRET and co-immunoprecipitation studies show that CD40 is recruited to the multi-molecular complex by B7-DC XAb. Signals emanating from CD40 are important, as CD40−/− DCs treated with B7-DC XAb (DCXAb) activated DAP12, but failed to activate NFκB, and were not protected from cell death upon cytokine withdrawal or treatment with Vitamin D3. CD40−/− DCXAb also failed to secrete IL-6 and were unable to support the conversion of T regulatory cells into IL-17+ effector T cells in vitro. Importantly, the expression of CD40 was required for the overall ability of B7-DC XAb to induce anti-tumor CTL, to provide protection from a number of tumor types, and for DCXAb to be effective anti-tumor vaccines in vivo. These results indicate that B7-DC XAb modulation of DC phenotypes is through its ability to indirectly recruit common signaling molecules and elements of their endogenous signaling pathways through targeted binding to a cell-specific surface determinant

Topics: Research Article
Publisher: Public Library of Science
OAI identifier:
Provided by: PubMed Central

Suggested articles


  1. (2000). 1-Alpha, 25-dihydroxyvitamin D3 inhibits differentiation, maturation, activation, and survival of dendritic cells leading to impaired alloreactive T cell activation.
  2. (2001). A DAP12-mediated pathway regulates expression of CC chemokine receptor 7 and maturation of human dendritic cells.
  3. (1994). Activation of human dendritic cells through CD40 cross-linking.
  4. (2008). An effective vaccine strategy protective against antigenically distinct tumor variants.
  5. (2005). B7-DC cross-linking restores antigen uptake and augments antigen-presenting cell function by matured dendritic cells.
  6. (2007). B7-DC/PD-L2 cross-linking induces NF-kappaB-dependent protection of dendritic cells from cell death.
  7. (2004). Blockade of allergic airway inflammation following systemic treatment with a B7-dendritic cell (PD-L2) cross-linking human antibody.
  8. (2002). CD40 induces interleukin-6 gene transcription in dendritic cells: regulation by TRAF2, AP-1, NF-kappa B, and CBF1.
  9. (2002). CD40 ligation conditions dendritic cell antigenpresenting function through sustained activation of NF-kappaB.
  10. (2002). CD40 signaling in B cells regulates the expression of the Pim-1 kinase via the NF-kappa B pathway.
  11. (2002). CD40 triggering increases the efficiency of dendritic cells for antitumoral immunization.
  12. (2005). CD40-dependent activation of phosphatidylinositol 3-kinase/AKT pathway inhibits apoptosis of human cultured mesangial cells induced by oxidized LDL.
  13. (2003). CD40-mediated transcriptional regulation of the IL-6 gene in B lymphocytes: involvement of NF-kappa B, AP-1, and C/EBP.
  14. (2004). CD40/CD154 interactions at the interface of tolerance and immunity.
  15. (2007). Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody.
  16. (2003). Cooperation of TNF family members CD40 ligand, receptor activator of NF-kappa B ligand, and TNF-alpha in the activation of dendritic cells and the expansion of viral specific CD8+ T cell memory responses in HIV-1-infected and HIV-1-uninfected individuals.
  17. (2002). Crosslinking the B7 family molecule B7-DC directly activates immune functions of dendritic cells.
  18. (2002). Dendritic cell development and survival require distinct NF-kappaB subunits.
  19. (2005). Dendritic cells activated by cross-linking B7-DC (PD-L2) block inflammatory airway disease.
  20. (1997). Dendritic cells genetically modified with an adenovirus vector encoding the cDNA for a model antigen induce protective and therapeutic antitumor immunity.
  21. (2000). Dendritic cells modified to express CD40 ligand elicit therapeutic immunity against preexisting murine tumors.
  22. (2007). Fast-tracked CTL: rapid induction of potent anti-tumor killer T cells in situ.
  23. (1992). Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor.
  24. (2006). Immunomodulation using the recombinant monoclonal human B7-DC cross-linking antibody rHIgM12.
  25. (2004). Immunotherapeutic potential of B7-DC (PD-L2) cross-linking antibody in conferring antitumor immunity.
  26. (2006). Induction of a gene expression program in dendritic cells with a crosslinking IgM antibody to the co-stimulatory molecule B7-DC.
  27. (1998). Interleukin 12-mediated prevention of spontaneous mammary adenocarcinomas in two lines of Her-2/neu transgenic mice.
  28. (2001). Monomeric class I molecules mediate TCR/CD3 epsilon/CD8 interaction on the surface of T cells.
  29. (2003). Naturally occurring human IgM antibody that binds B7-DC and potentiates T cell stimulation by dendritic cells.
  30. (2006). Rapid CD40-mediated rescue from CD95-induced apoptosis requires TNFR-associated factor-6 and PI3K.
  31. (2008). Reprogrammed FoxP3+ T regulatory cells become IL-17+ antigenspecific autoimmune effectors in vitro and in vivo.
  32. (2008). TREM-2 mediated signaling induces antigen uptake and retention in mature myeloid dendritic cells.
  33. (2003). TREMs in the immune system and beyond.
  34. (2008). Turning NF-kappaB and IRFs on and off in DC.

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.